Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Travoprost is the Alcon trade name for fluprostenol isopropyl ester, an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug.1,2 Travoprost is the active ingredient in Alcon’s Travatan brand ophthalmic solution. Fluprostenol isopropyl ester is a prodrug which is converted by esterase enzymatic activity in the cornea to yield the corresponding free acid.3 The free acid, fluprostenol, is a potent FP receptor agonist.4 In human and animal models of glaucoma, FP receptor agonist activity corresponds very closely with intraocular hypotensive activity.
1
Sorbera, L.A., and Castañer, J. Travoprost. Drugs Future2541-45(2000).
2
Hellberg, M.R., Sallee, V.L., Mclaughlin, M.A., et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther17(5)421-432(2001).
3
Stjernschantz, J., and Resul, B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future17691-704(1992).
4
Abramovitz, M., Adam, M., Boie, Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta1483285-293(2000).
Stjernschantz, J., and Resul, B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future17691-704(1992).
Abramovitz, M., Adam, M., Boie, Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta1483285-293(2000).
Sorbera, L.A., and Castañer, J. Travoprost. Drugs Future2541-45(2000).
Hellberg, M.R., Sallee, V.L., Mclaughlin, M.A., et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther17(5)421-432(2001).